Original Research
Accepted on 09 Feb 2026
Vitiligo secondary to Immunosuppressants: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
in Immunological Memory
Frontiers in Immunology
- 112 views
204 articles related to "Fda Adverse Event Reporting System Faers"
Articles
Original Research
Accepted on 10 Feb 2026
Disproportionality Analysis of Adverse Events Associated with Endothelin Receptor Antagonists Based on the FDA Adverse Event Reporting System (FAERS)
in Cardiovascular Pharmacology and Drug Discovery
Frontiers in Cardiovascular Medicine
- 213 views
Original Research
Published on 24 Jul 2024
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1407709
- 5,092 views
- 9 citations
Original Research
Published on 21 Dec 2023
A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1320458
- 15,102 views
- 54 citations
Original Research
Published on 25 Jun 2024
A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1405023
- 6,109 views
- 7 citations
Original Research
Published on 09 Apr 2024
A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1251961
- 8,285 views
- 19 citations
Original Research
Published on 11 Jan 2023
Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
in Pediatric Infectious Diseases
Frontiers in Pediatrics
doi 10.3389/fped.2022.1069504
- 7,460 views
- 10 citations
Original Research
Published on 10 Oct 2025
A real-world data analysis of piroxicam in the FDA Adverse Event Reporting System (FAERS) database
in Regulatory Science
Frontiers in Medicine
doi 10.3389/fmed.2025.1687088
- 1,926 views
Original Research
Published on 12 Mar 2025
Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1521358
- 9,961 views
- 7 citations
Original Research
Published on 07 Jun 2024
A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1397029
- 16,264 views
- 15 citations
Original Research
Published on 07 Aug 2024
Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
in Drugs Outcomes Research and Policies
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1391356
- 10,723 views
- 23 citations
Original Research
Published on 30 Aug 2024
A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
in Drugs Outcomes Research and Policies
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1339721
- 4,639 views
- 9 citations
Original Research
Published on 05 Jan 2026
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1714173
- 1,463 views
Original Research
Published on 11 Nov 2025
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1693090
- 2,577 views
Original Research
Published on 15 Dec 2022
Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
in Drugs Outcomes Research and Policies
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1039867
- 10,633 views
- 26 citations
Original Research
Published on 26 Jan 2026
Analysis of ASMs and male infertility using the FDA adverse event reporting system (FAERS)
in Life-Course Epidemiology and Social Inequalities in Health
Frontiers in Public Health
doi 10.3389/fpubh.2025.1738546
- 2,303 views